US stock futures steady after Wall St soars on dovish Powell; Nvidia earnings due
On Wednesday, JMP Securities reiterated its Market Outperform rating on Abivax (NASDAQ:ABVX) with a steady price target of $33.00, significantly above the current trading price of $7.12. The firm’s analyst highlighted the recent completion of Phase 3 enrollment for the drug obefazimod, which is being tested for the treatment of ulcerative colitis, and maintained a positive outlook on the stock’s potential. According to InvestingPro data, analyst consensus remains bullish with price targets ranging from $12 to $50, though investors should note the stock’s high volatility and rapid cash burn rate.
Abivax announced yesterday that it had successfully completed the enrollment for its two Phase 3 induction trials for obefazimod. This marks a significant step forward in the drug’s development process. The company’s management has confirmed that they expect to report top-line results from these trials in the third quarter of 2025, with an assumption that the findings could be released around late July or early August of the same year. With a market capitalization of $450 million and a current ratio of 1.82, InvestingPro analysis indicates the company maintains adequate liquidity for its near-term operations.
The JMP analyst noted that the blinded baseline characteristics provided by Abivax indicate that the patient population in the Phase 3 trials aligns with those from the Phase 2b trial. This consistency is particularly relevant for patients who have previously failed advanced therapy. The analyst’s confidence is further bolstered by the strong efficacy and safety profile demonstrated by obefazimod during the Phase 2b trials, as well as what is described as an optimized design for the ongoing Phase 3 trials.
The firm continues to expect positive outcomes from the Phase 3 trials based on these factors. Such results could potentially lead to a new treatment option for patients with ulcerative colitis, a chronic inflammatory bowel disease that can have a significant impact on quality of life.
The $33 price target set by JMP Securities is based on a risk-adjusted, discounted cash flow (DCF) analysis. This method takes into account the present value of estimated future cash flows, adjusting for the risk of investment, to derive a valuation for the company’s stock. Based on comprehensive financial analysis from InvestingPro, which considers factors such as the company’s Financial Health Score of 1.92 (rated as ’FAIR’) and current market conditions, the stock appears to be trading near its Fair Value. Subscribers to InvestingPro can access detailed valuation metrics and 8 additional ProTips to make more informed investment decisions.
In other recent news, Abivax has made significant strides with its lead drug candidate, obefazimod, which is undergoing Phase 3 clinical trials for ulcerative colitis. The company recently appointed Dr. Dominik Höchli to its Board of Directors, bringing his extensive experience in immunology, which is expected to be beneficial as the company approaches key trial results in 2025. Guggenheim has reiterated a Buy rating for Abivax, with confidence in the completion of the Phase 3 ABTECT UC trials and top-line results anticipated by the third quarter of 2025. Similarly, BTIG maintains a Buy rating and a $43 price target, citing the potential of obefazimod to meet the unmet needs of ulcerative colitis patients.
Morgan Stanley (NYSE:MS), however, has set an Equalweight rating with a $12 price target, highlighting the importance of upcoming Phase 3 trial results as a significant milestone for the company. The analysts noted the drug’s promise as a safe oral option for treatment-experienced patients. Meanwhile, JMP Securities continues to hold a Market Outperform rating with a $33 price target, supported by insights from a recent key opinion leader event that underscored obefazimod’s potential. Abivax’s financial position appears robust, with sufficient cash reserves to support operations into late 2025, aligning with the timeline for the trial results. These developments reflect a period of anticipation and strategic positioning for Abivax as it advances its pipeline in the competitive landscape of inflammatory bowel disease treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.